Thierry Andr News Today

Thierry André, MD, discusses the investigation of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer, including how its use as a standard of care in the third line supported its investigation in the first-line setting, the regimen’s efficacy and safety in the SOLSTICE trial, and the importance of this combination for patients in this space despite negative trial results.

No improvement in PFS versus standard for older patients ineligible for intensive therapy

Servier, a global independent pharmaceutical group, announced today that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours GlaxoSmithKline’s (GSK) dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. The updated data comes from cohort F of GSKs GARNET trial, which enrolled patients with mismatch repair-deficient (dMMR) non-endometrial advanced solid ca...